Experienced in SVC Obstruction

You Y. Lu

301 Middle Yanchang Road, 
Shanghai, CN 
Experienced in SVC Obstruction
301 Middle Yanchang Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

You Lu practices in Shanghai, China. Mr. Lu is rated as an Experienced expert by MediFind in the treatment of SVC Obstruction. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Thrombectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 281 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of SVC Obstruction.

Gender
Male

Locations

301 Middle Yanchang Road, Shanghai, 200072, China
Other Locations
G03, 1# Yao Cheng Avenue, Taizhou, China
Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer
A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
Study Phase: Phase 2
A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer
A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2024
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, Etoposide, and Cisplatin/Carboplatin
Study Phase: Phase 2
View 1 Less Clinical Trial

281 Total Publications

Improving the efficacy of late-line immunotherapy for advanced esophageal cancer: the addition of local radiotherapy.
Improving the efficacy of late-line immunotherapy for advanced esophageal cancer: the addition of local radiotherapy.
Journal: Therapeutic advances in gastroenterology
Published: June 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lu's expertise for a condition
ConditionClose
      View All 51 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile